Developing new drugs to fight antibiotic-resistant bacteria.
CHEMISTRY CENTER FOR COMBATING ANTIBIOTIC-RESISTANT BACTERIA (CC4CARB)
['FUNDING_OTHER'] · RESEARCH TRIANGLE INSTITUTE · NIH-10788038
This study is working on creating new chemical compounds to help scientists find better antibiotics for tough infections caused by Gram-negative bacteria, which could lead to more effective treatments for patients dealing with antibiotic-resistant infections.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RESEARCH TRIANGLE INSTITUTE (nih funded) |
| Locations | 1 site (RESEARCH TRIANGLE PARK, UNITED STATES) |
| Trial ID | NIH-10788038 on ClinicalTrials.gov |
What this research studies
The Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB) focuses on creating and providing a variety of specially designed chemical compounds to help scientists discover new antibacterial medications. This initiative specifically targets Gram-negative bacteria, which are known for their resistance to many existing antibiotics. By synthesizing these compound libraries, the research aims to support the scientific community in finding effective treatments against these challenging infections. Patients may benefit from the eventual development of new antibiotics that can effectively treat resistant bacterial infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from infections caused by Gram-negative bacteria that are resistant to current antibiotic treatments.
Not a fit: Patients with infections caused by non-Gram-negative bacteria or those who do not have antibiotic-resistant infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antibiotics that effectively treat infections caused by antibiotic-resistant bacteria.
How similar studies have performed: Other research initiatives targeting antibiotic resistance have shown promise in developing new treatments, indicating that this approach has potential for success.
Where this research is happening
RESEARCH TRIANGLE PARK, UNITED STATES
- RESEARCH TRIANGLE INSTITUTE — RESEARCH TRIANGLE PARK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BLOUGH, BRUCE — RESEARCH TRIANGLE INSTITUTE
- Study coordinator: BLOUGH, BRUCE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.